Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044.
June 09, 2026 06:00 ET | Source: Treos Bio Corp.

TREOS Bio Presents New PEPI Technology Data at EACR 2026, Including Six-Year Cancer-Free Outcome in MSS Metastatic Colorectal Cancer (mCRC)

LONDON and BOSTON and BUDAPEST, Hungary, June 09, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage company developing off-the-shelf and personalized active cancer immunotherapies, today...
June 08, 2026 06:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in...
June 02, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.
June 01, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.
June 01, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
May 15, 2026 09:49 ET | Source: BCC Research LLC

AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment

How chronic disease prevalence, infectious disease testing, AI investment, personalized medicine and regulatory change are shaping the diagnostics industry
May 14, 2026 07:45 ET | Source: Research and Markets

C-Met-Targeted Immunotherapies Pipeline Competitive Intelligence Report 2026: CCR8-targeted R&D Programs and Profile of CCR8-targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of c-Met-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
May 13, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight

New York, USA, May 13, 2026 (GLOBE NEWSWIRE) -- Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight The...
May 08, 2026 09:07 ET | Source: Research and Markets

AI in Oncology Research Report 2026 - Global Market Forecast to 2036: Intensifying Focus on Precision Medicine and the Rapid Expansion of Intelligent Diagnostic Frameworks

Dublin, May 08, 2026 (GLOBE NEWSWIRE) -- The "AI in Oncology Market by Component, Cancer Type, and Application - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.Global...